ESSEX BIO-TECH Reports Stable Share Capital and Confirms Public Float Compliance for May 2026

Bulletin Express06-02

Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital.

Authorised Share Capital • Remained at 1.00 billion ordinary shares with HKD 0.10 par value, equal to HKD 100.00 million.

Issued Shares and Treasury Shares • Issued ordinary shares stood unchanged at 567.01 million. • The company held no treasury shares during the month. • No new shares were issued, repurchased or cancelled in May.

Public Float Status • The company confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 May 2026.

Share Option Scheme Capacity • The 2023 Share Option Scheme has capacity for up to 57.06 million shares; however, no options were outstanding or exercised during the month.

Overall, ESSEX BIO-TECH’s capital structure and share count remained steady throughout May 2026, with regulatory float requirements fully satisfied.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122040423?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122040423","market":"us","top_or_hot":-1,"title":"ESSEX BIO-TECH Reports Stable Share Capital and Confirms Public Float Compliance for May 2026","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital.</p>\n<p>Authorised Share Capital  \n• Remained at 1.00 billion ordinary shares with HKD 0.10 par value, equal to HKD 100.00 million.</p>\n<p>Issued Shares and Treasury Shares  \n• Issued ordinary shares stood unchanged at 567.01 million.  \n• The company held no treasury shares during the month.  \n• No new shares were issued, repurchased or cancelled in May.</p>\n<p>Public Float Status  \n• The company confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 May 2026.</p>\n<p>Share Option Scheme Capacity  \n• The 2023 Share Option Scheme has capacity for up to 57.06 million shares; however, no options were outstanding or exercised during the month.</p>\n<p>Overall, ESSEX BIO-TECH’s capital structure and share count remained steady throughout May 2026, with regulatory float requirements fully satisfied.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSEX BIO-TECH Reports Stable Share Capital and Confirms Public Float Compliance for May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSEX BIO-TECH Reports Stable Share Capital and Confirms Public Float Compliance for May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 12:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital.</p>\n<p>Authorised Share Capital  \n• Remained at 1.00 billion ordinary shares with HKD 0.10 par value, equal to HKD 100.00 million.</p>\n<p>Issued Shares and Treasury Shares  \n• Issued ordinary shares stood unchanged at 567.01 million.  \n• The company held no treasury shares during the month.  \n• No new shares were issued, repurchased or cancelled in May.</p>\n<p>Public Float Status  \n• The company confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 May 2026.</p>\n<p>Share Option Scheme Capacity  \n• The 2023 Share Option Scheme has capacity for up to 57.06 million shares; however, no options were outstanding or exercised during the month.</p>\n<p>Overall, ESSEX BIO-TECH’s capital structure and share count remained steady throughout May 2026, with regulatory float requirements fully satisfied.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1122040423","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122040423","pubTimestamp":1780374193,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital. Authorised Share Capital   •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"ESSEX BIO-TECH报告股本稳定并确认2026年5月公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited (ESSEX BIO-TECH) filed its Monthly Return for the period ended 31 May 2026, showing no movement in either authorised or issued share capital.\nAuthorised Share Capital  \n• Remained at 1.00 billion ordinary shares with HKD 0.10 par value, equal to HKD 100.00 million.\nIssued Shares and Treasury Shares  \n• Issued ordinary shares stood unchanged at 567.01 million.  \n• The company held no treasury shares during the month.  \n• No new shares were issued, repurchased or cancelled in May.\nPublic Float Status  \n• The company confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 May 2026.\nShare Option Scheme Capacity  \n• The 2023 Share Option Scheme has capacity for up to 57.06 million shares; however, no options were outstanding or exercised during the month.\nOverall, ESSEX BIO-TECH’s capital structure and share count remained steady throughout May 2026, with regulatory float requirements fully satisfied.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122040423","isCrawlerRequest":true}